Publication:
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Simple item page
dc.contributor.authorTÜRK, HACI MEHMET
dc.contributor.authorTsuboi M.
dc.contributor.authorHerbst R. S.
dc.contributor.authorJohn T.
dc.contributor.authorKato T.
dc.contributor.authorMajem M.
dc.contributor.authorGrohé C.
dc.contributor.authorWang J.
dc.contributor.authorGoldman J. W.
dc.contributor.authorLu S.
dc.contributor.authorSu W.
dc.contributor.authoret al.
dc.date.accessioned2023-08-01T21:50:13Z
dc.date.available2023-08-01T21:50:13Z
dc.date.issued2023-07-13
dc.identifier.citationTsuboi M., Herbst R. S., John T., Kato T., Majem M., Grohé C., Wang J., Goldman J. W., Lu S., Su W., et al., "Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.", The New England journal of medicine, cilt.389, sa.2, ss.137-147, 2023
dc.identifier.doi10.1056/nejmoa2304594
dc.identifier.endpage147
dc.identifier.issn0028-4793
dc.identifier.issue2
dc.identifier.pubmed37272535
dc.identifier.startpage137
dc.identifier.urihttps://hdl.handle.net/20.500.12645/38493
dc.identifier.volume389
dc.relation.ispartofThe New England journal of medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
dc.typeArticle
dspace.entity.typePublication
local.avesis.id600e078f-4b0a-468d-8c2f-18b323a1cf03
local.indexed.atPubMed
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29

Files

Collections

Yayınlar - Eserler